Do analysts recommend 4BB or IXI?

4basebio presently has a consensus price target of GBX 1,600, suggesting a potential upside of 202.23%. Given 4basebio's stronger consensus rating and higher possible upside, research analysts plainly believe 4basebio is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, 4BB or IXI?

IXICO has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4basebio £1.78M 46.08 -£9.84M -£99.00 N/A IXICO £7.28M 2.49 -£3.58M -£1.85 N/A

Is 4BB or IXI more profitable?

4basebio has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% IXICO -24.98% -16.18% -10.40%

Does the media refer more to 4BB or IXI?

In the previous week, 4basebio and 4basebio both had 4 articles in the media. IXICO's average media sentiment score of 1.03 beat 4basebio's score of 1.01 indicating that IXICO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4basebio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IXICO 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, IXI or ORPH?

Open Orphan has higher revenue and earnings than IXICO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.49 -£3.58M -£1.85 N/A Open Orphan £34.71M 0.00 N/A N/A N/A

Is IXI or ORPH more profitable?

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% Open Orphan N/A N/A N/A

Which has preferable earnings & valuation, IXI or REDX?

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.49 -£3.58M -£1.85 N/A Redx Pharma £4.20M 0.00 -£33.16M -£0.10 N/A

Is IXI or REDX more profitable?

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% Redx Pharma N/A -180.80% -43.95%

Do analysts prefer IXI or HVO?

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 85.19%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger earnings & valuation, IXI or HVO?

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.49 -£3.58M -£1.85 N/A hVIVO £46.77M 1.19 £17.84M -£0.87 N/A

Is IXI or HVO more profitable?

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% hVIVO -12.48% -14.65% 11.97%

Does the media prefer IXI or HVO?

In the previous week, IXICO had 2 more articles in the media than hVIVO. MarketBeat recorded 4 mentions for IXICO and 2 mentions for hVIVO. IXICO's average media sentiment score of 1.03 beat hVIVO's score of 0.00 indicating that IXICO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IXICO 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive hVIVO 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, IXI or ETX?

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.49 -£3.58M -£1.85 N/A e-therapeutics £295K 0.00 -£10.06M -£0.02 N/A

Is IXI or ETX more profitable?

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% e-therapeutics N/A -38.75% -29.10%

IXICO (IXI) Competitors

GBX 8.70 -0.05 (-0.57%)

As of 12:27 PM Eastern

Compare

IXI vs. 4BB, ORPH, REDX, HVO, and ETX

Should you buy IXICO stock or one of its competitors? MarketBeat compares IXICO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IXICO include 4basebio (4BB), Open Orphan (ORPH), Redx Pharma (REDX), hVIVO (HVO), and e-therapeutics (ETX). These companies are all part of the "biotechnology" industry.

How does IXICO compare to 4basebio?

4basebio (LON:4BB) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

4basebio presently has a consensus price target of GBX 1,600, suggesting a potential upside of 202.23%. Given 4basebio's stronger consensus rating and higher possible upside, research analysts plainly believe 4basebio is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4basebio has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, IXICO has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

IXICO has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.78M	46.08	-£9.84M	-£99.00	N/A
IXICO	£7.28M	2.49	-£3.58M	-£1.85	N/A

4basebio has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
IXICO	-24.98%	-16.18%	-10.40%

In the previous week, 4basebio and 4basebio both had 4 articles in the media. IXICO's average media sentiment score of 1.03 beat 4basebio's score of 1.01 indicating that IXICO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4basebio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IXICO	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.9% of 4basebio shares are held by institutional investors. Comparatively, 4.7% of IXICO shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 6.0% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

IXICO beats 4basebio on 8 of the 15 factors compared between the two stocks.

How does IXICO compare to Open Orphan?

IXICO (LON:IXI) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, IXICO had 4 more articles in the media than Open Orphan. MarketBeat recorded 4 mentions for IXICO and 0 mentions for Open Orphan. IXICO's average media sentiment score of 1.03 beat Open Orphan's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
Open Orphan	Neutral

Open Orphan has a net margin of 0.00% compared to IXICO's net margin of -24.98%. Open Orphan's return on equity of 0.00% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Open Orphan	N/A	N/A	N/A

Open Orphan has higher revenue and earnings than IXICO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.49	-£3.58M	-£1.85	N/A
Open Orphan	£34.71M	0.00	N/A	N/A	N/A

4.7% of IXICO shares are held by institutional investors. 6.0% of IXICO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

IXICO beats Open Orphan on 5 of the 9 factors compared between the two stocks.

How does IXICO compare to Redx Pharma?

IXICO (LON:IXI) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Redx Pharma	N/A	-180.80%	-43.95%

IXICO has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market.

In the previous week, IXICO had 4 more articles in the media than Redx Pharma. MarketBeat recorded 4 mentions for IXICO and 0 mentions for Redx Pharma. IXICO's average media sentiment score of 1.03 beat Redx Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
Redx Pharma	Neutral

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.49	-£3.58M	-£1.85	N/A
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A

4.7% of IXICO shares are held by institutional investors. Comparatively, 72.7% of Redx Pharma shares are held by institutional investors. 6.0% of IXICO shares are held by company insiders. Comparatively, 18.4% of Redx Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

IXICO beats Redx Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to hVIVO?

IXICO (LON:IXI) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

IXICO has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, hVIVO has a beta of 1.685, suggesting that its share price is 69% more volatile than the broader market.

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
hVIVO	-12.48%	-14.65%	11.97%

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.49	-£3.58M	-£1.85	N/A
hVIVO	£46.77M	1.19	£17.84M	-£0.87	N/A

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 85.19%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

4.7% of IXICO shares are held by institutional investors. Comparatively, 10.2% of hVIVO shares are held by institutional investors. 6.0% of IXICO shares are held by insiders. Comparatively, 5.2% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IXICO had 2 more articles in the media than hVIVO. MarketBeat recorded 4 mentions for IXICO and 2 mentions for hVIVO. IXICO's average media sentiment score of 1.03 beat hVIVO's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IXICO	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
hVIVO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

hVIVO beats IXICO on 11 of the 16 factors compared between the two stocks.

How does IXICO compare to e-therapeutics?

IXICO (LON:IXI) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

In the previous week, IXICO had 4 more articles in the media than e-therapeutics. MarketBeat recorded 4 mentions for IXICO and 0 mentions for e-therapeutics. IXICO's average media sentiment score of 1.03 beat e-therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
e-therapeutics	Neutral

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.49	-£3.58M	-£1.85	N/A
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A

IXICO has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
e-therapeutics	N/A	-38.75%	-29.10%

4.7% of IXICO shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 6.0% of IXICO shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

IXICO beats e-therapeutics on 7 of the 12 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£18.10M	£461.45M	£6.44B	£2.81B
Dividend Yield	1.27%	3.86%	2.75%	6.08%
P/E Ratio	-4.49	3.39	21.50	365.45
Price / Sales	2.49	7,002.25	581.08	87,990.19
Price / Cash	2.25	13.13	43.13	27.89
Price / Book	0.42	85.56	10.51	7.75
Net Income	-£3.58M	-£96.07M	£3.56B	£5.89B
7 Day Performance	N/A	1.06%	2.96%	1.40%
1 Month Performance	19.79%	2.78%	4.40%	4.10%
1 Year Performance	-33.49%	88.76%	37.72%	69.73%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 8.70 -0.6%	N/A	-31.6%	£18.97M	£7.28M	N/A	89	Positive News Gap Down
4BB 4basebio	2.9685 of 5 stars	GBX 450 -13.5%	GBX 1,600 +255.6%	-54.0%	£69.68M	£1.78M	N/A	101	Gap Down
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
HVO hVIVO	1.9741 of 5 stars	GBX 8.10 +2.9%	GBX 15 +85.2%	-49.9%	£55.76M	£46.77M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 5/28/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors